As the world’s largest vaccine manufacturer by volume of doses produced, the Pune-based Serum Institute of India is among the keenly-watched companies in the race for a COVID-19 vaccine. It is partnering with the Oxford University-AstraZeneca vaccine project, apart from two other candidates, in initial trials. Adar Poonawalla, CEO of Serum Institute, tells Ajay Sukumaran via email that he’s expecting the Indian trials of the Oxford vaccine to be over in January 2021. Edited excerpts:
How close is Oxford-AstraZeneca to delivering its COVID-19 vaccine under an emergency licence in the UK? How soon do you hope to get efficacy and safety data from your trials in India?